# A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

> **NCT06699121** · PHASE2 · RECRUITING · sponsor: **LISCure Biosciences** · enrollment: 87 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis (PSC)

## Interventions

- **DRUG:** LB-P8 low-dose
- **DRUG:** LB-P8 high-dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06699121
- **Lead sponsor:** LISCure Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2028-03
- **Final completion:** 2029-02
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699121, "A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06699121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*